A subsequent study showed that urinary excretion of LTE4 was significantly higher in CML patients than healthy controls, supporting the increased LTC4 synthase activity in CML patients; they further found that neutrophilic LTC4 synthase expression and activity were markedly elevated and were normalized with imatinib mesylate treatment [98]. The gene discussed is LTC4S; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.